BioCryst Pharmaceuticals (BCRX) closed the last trading session at $7.95, gaining 4.2% over the past four weeks, but there ...
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on BioCryst (BCRX – Research Report) today. The company’s shares opened today at $7.62. Ahmad covers the Healthcare sector, ...
Zacks.com on MSN11d
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue EstimatesBioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago. These figures are ...
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have earned a consensus recommendation of “Moderate ...
A Durham company says its drug is pacing for over $400 million in revenue this year. The goal is $1 billion.
Evercore ISI analyst Liisa Bayko maintained a Buy rating on BioCryst (BCRX – Research Report) today and set a price target of $10.00. The ...
Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) — — Company ...
Short interest in BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) decreased during the last reporting period, falling from 23.23M to 22.53M. This put 10.98% of the company's publicly available shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback